Overview
Bifidobacterium animalis subsp. lactis CECT8145 is a probiotic strain belonging to the B. animalis species, commonly used in functional foods and dietary supplements. While specific human clinical trials on CECT8145 are not detailed in the provided literature, related research on B. animalis strains indicates potential benefits including modulation of gut microbiota, enhancement of intestinal barrier function, and immunomodulatory effects [2]. Probiotics like B. animalis are thought to act through mechanisms such as competitive exclusion of pathogens and interaction with host immune cells. However, B. animalis strains, including those closely related to CECT8145, show limited growth in human milk and higher susceptibility to lysozyme compared to human-derived bifidobacteria, which may influence their survival in the gastrointestinal tract [1]. Despite this, B. animalis strains are widely consumed and considered safe, with evidence supporting their fecal recovery after oral administration, suggesting transient gut presence [6].
Dosage Guide
Therapeutic Doses
For treatment of specific conditions
Special Forms
Alternative forms for specific needs
Enhanced gastric acid resistance and improved viability through GI tract
Common delivery format in supplements and functional foods
Clinical Notes
- No specific adverse effects reported for B. animalis strains in healthy populations, but caution advised in immunocompromised individuals
- Probiotic effects are strain-specific; benefits of related strains do not guarantee identical outcomes for CECT8145
- Ensure product viability through expiration date via CFU labeling and proper storage
Research
B. animalis strains are inhibited by human milk and more susceptible to lysozyme compared to human-derived bifidobacteria like B. bifidum.
Probiotic benefits may arise from shared mechanisms within taxonomic groups, supporting potential genus- or species-level effects for Bifidobacterium.
CECT strains such as L. fermentum CECT5716 exhibit immunomodulatory and anti-inflammatory actions, suggesting possible similar mechanisms for other CECT-designated probiotics.
Bacteroides uniformis CECT7771 was safe in a 90-day sub-chronic trial, supporting safety assessment protocols for novel CECT strains.
L. fermentum CECT5716 was safe and well-tolerated in infants, indicating a favorable safety profile for CECT-designated probiotic strains in vulnerable populations.
Oral supplementation with B. infantis 35624 increased fecal excretion, indicating survival through the GI tract, a relevant finding for B. animalis strain delivery.
Probiotics are generally safe with rare adverse events, supporting the safety of well-characterized strains like B. animalis.
Bifidobacterium longum strains were well-tolerated in adults with no adverse immune changes, supporting the safety of bifidobacteria in human consumption.
